Art. -Nr.: HY-16026

Ricolinostat

Name: Ricolinostat
Brand: MedChemExpress
SKU: HY-16026
Price: 55.00 USD
Availability: InStock
Rating: 5 (47 reviews)

(Synonyms: ACY-1215; Rocilinostat)

47 Cited Publications

Kundenbewertung

Based on 47 publication(s) in Google Scholar

Ricolinostat (ACY-1215) is a potent and selective HDAC6 inhibitor, with an IC₅₀ of 5 nM. ACY-1215 also inhibits HDAC1, HDAC2, and HDAC3 with IC₅₀s of 58, 48, and 51 nM, respectively.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.83%
CAS. Nr.: 1316214-52-4
Formel: C₂₄H₂₇N₅O₃
Molecular Weight:433.50

Speicherung:

4°C, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)

Ricolinostat Chemical Structure

CAS. Nr.: 1316214-52-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (47)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HDAC6

4.7 nM (IC₅₀)

HDAC2

48 nM (IC₅₀)

HDAC3

51 nM (IC₅₀)

HDAC1

58 nM (IC₅₀)

HDAC8

100 nM (IC₅₀)

HDAC7

1400 nM (IC₅₀)

HDAC5

5000 nM (IC₅₀)

HDAC4

7000 nM (IC₅₀)

Alle HDAC Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
697	IC₅₀	201 nM Compound: Ricolinostat	Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay	[PMID: 31710483]
A2780	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 26443078]
A549	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26443078]
A549	IC₅₀	7.7 μM Compound: ACY1215	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30525585]
HAL-01	IC₅₀	>25 μM Compound: Ricolinostat	Anticancer activity against human HAL-01 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay Anticancer activity against human HAL-01 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay	[PMID: 34582215]
HAL-01	IC₅₀	2.04 μM Compound: Ricolinostat	Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HAL-01 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
HCT-116	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26443078]
HCT-116	IC₅₀	1.85 μM Compound: ACY-1215	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
HEL	IC₅₀	2.54 μM Compound: 28; ACY1215	Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay	[PMID: 29940115]
HEL	IC₅₀	3.75 μM Compound: 28; ACY1215	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HeLa	IC₅₀	>5000 nM Compound: ACY-1215	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 26443078]
HepG2	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 26443078]
HL-60	IC₅₀	2.54 μM Compound: 28; ACY1215	Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay	[PMID: 29940115]
HL-60	IC₅₀	3.75 μM Compound: 28; ACY1215	Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HL-60	IC₅₀	2.36 μM Compound: Ricolinostat	Cytotoxicity against human HL60 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human HL60 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
HL-60	IC₅₀	>10000 nM Compound: Ricolinostat	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability for 72 hrs by Celltitre-Glo luminescent assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability for 72 hrs by Celltitre-Glo luminescent assay	[PMID: 33360560]
HL-60	IC₅₀	10.37 μM Compound: Ricolinostat	Anticancer activity against human HL-60 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay Anticancer activity against human HL-60 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay	[PMID: 34582215]
HL-60	IC₅₀	1.54 μM Compound: Ricolinostat	Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
HPBALL	IC₅₀	6.7 μM Compound: Ricolinostat	Anticancer activity against human HPBALL cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay Anticancer activity against human HPBALL cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay	[PMID: 34582215]
HT-29	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 26443078]
HUVEC	IC₅₀	13.62 μM Compound: ACY-1215	Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
Jurkat	IC₅₀	2.42 μM Compound: Ricolinostat	Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36351184]
K562	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 26443078]
K562	IC₅₀	2.54 μM Compound: 28; ACY1215	Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay	[PMID: 29940115]
K562	IC₅₀	3.75 μM Compound: 28; ACY1215	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
K562	IC₅₀	6.02 μM Compound: Ricolinostat	Anticancer activity against human K562 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay Anticancer activity against human K562 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay	[PMID: 34582215]
KCL-22	IC₅₀	3.38 μM Compound: Ricolinostat	Cytotoxicity against imatinib-resistant human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against imatinib-resistant human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
KCL-22	IC₅₀	3.75 μM Compound: Ricolinostat	Cytotoxicity against human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human KCL22 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
KCL-22	IC₅₀	3.75 μM Compound: Ricolinostat	Cytotoxicity against human KCL-22 cells Cytotoxicity against human KCL-22 cells	[PMID: 33077264]
KM12	IC₅₀	2.15 μM Compound: ACY-1215	Antiproliferative activity against human KM12 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human KM12 cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
MDA-MB-468	IC₅₀	4.919 μM Compound: ACY-1215	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay	[PMID: 37797564]
MM1.S	IC₅₀	2 μM Compound: 18; ACY-1215	Cytotoxicity against human MM1.S cells incubated for 48 hrs by MTT assay Cytotoxicity against human MM1.S cells incubated for 48 hrs by MTT assay	[PMID: 29133060]
MM1.S	EC₅₀	0.85 nM Compound: ACY-1215	Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability after 144 hrs Antiproliferative activity against human MM1.S cells assessed as reduction in cell viability after 144 hrs	[PMID: 33359604]
MM1.S	IC₅₀	0.84 μM Compound: ACY-1215	Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis Cytotoxicity against human MM1.S cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	[PMID: 35119267]
MV4-11	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay Cytotoxicity against human MV4-11 cells after 72 hrs by MTT assay	[PMID: 26443078]
MV4-11	IC₅₀	0.656 μM Compound: 5	Cytotoxicity against human MV4-11 cells measured after 72 hrs by spectrophotometer method Cytotoxicity against human MV4-11 cells measured after 72 hrs by spectrophotometer method	[PMID: 32615502]
MV4-11	IC₅₀	0.81 μM Compound: ACY-1215	Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay Cytotoxicity against human MV4-11 cells assessed as cell viability incubated for 72 hrs by Cell titer-blue assay	[PMID: 34101461]
MV4-11	IC₅₀	0.656 μM Compound: ACY-1215	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs measured by spectrophotometer analysis	[PMID: 35119267]
MV4-11	EC₅₀	0.71 μM Compound: ACY-1215	Antiproliferative activity against human MV4-11 cells assessed as cell viability by measuring amount of ATP after 72 hrs incubation by CellTiteer-Glo Cell viability assay Antiproliferative activity against human MV4-11 cells assessed as cell viability by measuring amount of ATP after 72 hrs incubation by CellTiteer-Glo Cell viability assay	[PMID: 39067437]
NCI-H460	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 26443078]
NCI-H929	GI₅₀	>100 μM Compound: 3; ACY-1215	Antiproliferative activity against human NCI-H929 cells after 48 hrs by SRB assay Antiproliferative activity against human NCI-H929 cells after 48 hrs by SRB assay	[PMID: 29304284]
OPM-2	IC₅₀	2 μM Compound: 18; ACY-1215	Cytotoxicity against human OPM-2 cells incubated for 48 hrs by MTT assay Cytotoxicity against human OPM-2 cells incubated for 48 hrs by MTT assay	[PMID: 29133060]
PBMC	IC₅₀	<3.6 μM Compound: Ricolinostat	Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human PBMC after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
Ramos	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human Ramos cells after 72 hrs by MTT assay Cytotoxicity against human Ramos cells after 72 hrs by MTT assay	[PMID: 26443078]
REH	IC₅₀	>25 μM Compound: Ricolinostat	Anticancer activity against human REH cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay Anticancer activity against human REH cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay	[PMID: 34582215]
RPMI-8226	IC₅₀	1468 nM Compound: ACY-1215	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 26443078]
RPMI-8226	GI₅₀	6.4 μM Compound: 3; ACY-1215	Antiproliferative activity against human RPMI8226 cells after 48 hrs by SRB assay Antiproliferative activity against human RPMI8226 cells after 48 hrs by SRB assay	[PMID: 29304284]
RPMI-8226	IC₅₀	11 μM Compound: ACY-1215	Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay Growth inhibition of human RPMI8226 cells after 72 hrs by MTT assay	[PMID: 30594434]
RPMI-8226	IC₅₀	9.26 μM Compound: ACY-1215	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]
RPMI-8226	IC₅₀	1.5 μM Compound: 1; ACY-1215	Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 72 hrs by alamar blue dye based assay Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition incubated for 72 hrs by alamar blue dye based assay	[PMID: 37660484]
RPMI-8226	IC₅₀	1.191 μM Compound: ACY-1215	Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK8 assay	[PMID: 37797564]
SEM	IC₅₀	1.61 μM Compound: Ricolinostat	Cytotoxicity against human SEM cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SEM cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
SEM	IC₅₀	1.61 μM Compound: Ricolinostat	Cytotoxicity against human SEM cells Cytotoxicity against human SEM cells	[PMID: 33077264]
Sf9	IC₅₀	5 nM Compound: ACY-1215	Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	[PMID: 30594434]
Sf9	IC₅₀	74 nM Compound: ACY-1215	Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay Inhibition of full length recombinant human C-terminal FLAG-tagged HDAC1 expressed in sf9 cells preincubated for 5 mins followed by biotinylated H3K9-Ac substrate addition and measured after 60 mins by HTRF assay	[PMID: 30594434]
Sf9	IC₅₀	4.7 nM Compound: ACY-1215	Inhibition of recombinant human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells assessed as decrease in release of 7-amino-4-methoxycoumarin using FTS as substrate preincubated for 10 mins followed by substrate a Inhibition of recombinant human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells assessed as decrease in release of 7-amino-4-methoxycoumarin using FTS as substrate preincubated for 10 mins followed by substrate a	[PMID: 31414801]
Sf9	IC₅₀	58 nM Compound: ACY-1215	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in release of 7-amino-4-methoxycoumarin using FTS as substrate preincubated for 10 mins followed by substr Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells assessed as decrease in release of 7-amino-4-methoxycoumarin using FTS as substrate preincubated for 10 mins followed by substr	[PMID: 31414801]
Sf9	IC₅₀	12 nM Compound: Ricolinostat	Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method	[PMID: 31710483]
Sf9	IC₅₀	>1 μM Compound: ACY1215	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.379 μM Compound: ACY1215	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
SK-BR-3	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay Cytotoxicity against human SKBR3 cells after 72 hrs by MTT assay	[PMID: 26443078]
SK-OV-3	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 26443078]
SU-DHL-6	IC₅₀	0.83 μM Compound: ACY-1215	Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
SUP-B15	IC₅₀	1.92 μM Compound: Ricolinostat	Cytotoxicity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
SUP-B15	IC₅₀	3.54 μM Compound: Ricolinostat	Cytotoxicity against imatinib-resistant human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against imatinib-resistant human SUP-B15 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
T47D	IC₅₀	0.71 μM Compound: ACY-1215	Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
TALL-1	IC₅₀	3.88 μM Compound: Ricolinostat	Anticancer activity against human TALL-1 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay Anticancer activity against human TALL-1 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay	[PMID: 34582215]
U-266	IC₅₀	>5000 nM Compound: ACY-1215	Cytotoxicity against human U266 cells after 72 hrs by MTT assay Cytotoxicity against human U266 cells after 72 hrs by MTT assay	[PMID: 26443078]
U-266	GI₅₀	>100 μM Compound: 3; ACY-1215	Antiproliferative activity against human U266 cells after 48 hrs by SRB assay Antiproliferative activity against human U266 cells after 48 hrs by SRB assay	[PMID: 29304284]
U-266	IC₅₀	3.52 μM Compound: Ricolinostat	Cytotoxicity against human U266 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay Cytotoxicity against human U266 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30365892]
U-266	IC₅₀	21.2 μM Compound: ACY-1215	Growth inhibition of human U266 cells after 72 hrs by MTT assay Growth inhibition of human U266 cells after 72 hrs by MTT assay	[PMID: 30594434]
U-266	IC₅₀	>100 μM Compound: ACY-1215	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay	[PMID: 31865013]

In Vitro

Ricolinostat (ACY-1215) has slight activity against HDAC8 (IC₅₀=0.1 μM), and has minimal activity (IC₅₀>1 μM) against HDAC4, HDAC5, HDAC7, HDAC9, HDAC11, Sirtuin1, and Sirtuin2. The effect of Ricolinostat (ACY-1215) on multiple myeloma (MM) cell viability is determined with MTT assays using MM cell lines. Exposure of MM cell lines for 48 hours results in dose-dependent decreased viability, with IC₅₀ values ranging from 2-8μM. Ricolinostat (ACY-1215) demonstrates significant activity in the MM PS-341-resistant cell line (ANBL-6.BR), demonstrating the ability of Ricolinostat (ACY-1215) to overcome PS-341 resistance^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice treated with Ricolinostat (ACY-1215), PS-341, or Ricolinostat plus PS-341 show a significant delay in tumor growth (P=0.01, P=0.006, and P<0.0001, respectively). Combined treatment with Ricolinostat and PS-341 shows significant suppression of tumor growth and significantly prolonged overall survival (OS) compare with the control group (17 days in the control vs 40 days in the combination-treated group, P<0.0001) and the Ricolinostat (ACY-1215)-treated group (22 days in the PS-341 group vs 40 days in the combination-treated group, P<0.0001). Weight loss in the combination-treated group is between 4% and 12% compare with the same-day control group values during treatment, with complete recovery after the last injection. As is observed in the plasmacytoma model, a significant therapeutic advantage is found by combining Ricolinostat with PS-341 compare with either agent alone^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1316214-52-4
Appearance Solid
Molecular Weight 433.50
Formel C₂₄H₂₇N₅O₃
Color White to off-white
SMILES

O=C(C1=CN=C(N(C2=CC=CC=C2)C3=CC=CC=C3)N=C1)NCCCCCCC(NO)=O
Synonyms

ACY-1215; Rocilinostat
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen

* In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)

Publications (47)

All WB

Sort by:

Journal Impact Factor

Blood

Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia. [Abstract]

2019 Oct 17;134(16):1323-1336. PMID: 31492675
Nat Commun

Neural deficits in a mouse model of PACS1 syndrome are corrected with PACS1- or HDAC6-targeting therapy. [Abstract]

2023 Oct 17;14(1):6547. PMID: 37848409
J Exp Clin Cancer Res

CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages. [Abstract]

2025 Feb 24;44(1):67. PMID: 39994810
J Control Release

Activated hepatic stellate cell membrane-camouflaged nanomedicine enables targeted HDAC6 inhibition for liver fibrosis therapy. [Abstract]

2026 Jun 14:396:115100. PMID: 42289234
J Control Release

Polymer-based nanodrugs enhance sonodynamic therapy through epigenetic reprogramming of the immunosuppressive tumor microenvironment. [Abstract]

2025 Feb 5:380:125-137. PMID: 39892649
Cell Mol Biol Lett

IDH1/MDH1 deacetylation promotes acute liver failure by regulating NETosis. [Abstract]

2024 Jan 3;29(1):8. PMID: 38172700
Cancer Lett

HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. [Abstract]

2016 Aug 28;379(1):134-42. PMID: 27267806

Ricolinostat purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2016 Aug 28;379(1):134-42. [Abstract]

Inhibition of HDAC6 by HDAC6-selective inhibitors impairs the proliferation of glioblastoma cells. U87 and U251 cells are treated with HDAC6 selective inhibitors and the cells are harvested for subsequent western blot analysis.
J Neuroinflammation

Inhibition of histone deacetylase 6 alleviates neuropathic pain via direct regulating post-translation of spinal STAT3 and decreasing downstream C-C Motif Chemokine Ligand 7 synthesis. [Abstract]

2025 Mar 11;22(1):74. PMID: 40069860
Cell Death Discov

Deacetylated MDH1 and IDH1 aggravates PANoptosis in acute liver failure through endoplasmic reticulum stress signaling. [Abstract]

2024 Jun 8;10(1):275. PMID: 38851781
NPJ Precis Oncol

Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. [Abstract]

2024 Mar 7;8(1):66. PMID: 38454151
Oncogene

Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor. [Abstract]

2021 Mar;40(12):2323-2334. PMID: 33654196
Oncogene

Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway. [Abstract]

2018 Nov;37(45):5952-5966. PMID: 29980788

Ricolinostat purchased from MedChemExpress. Usage Cited in: Oncogene. 2018 Nov;37(45):5952-5966. [Abstract]

Mouse CAFs are treated with increasing concentrations of ACY1215 for 24 h. Western blot analysis of tubulin, histone H3, histone H4, acetylated tubulin, acetylated histone H3, and acetylated histone H4.
Leukemia

Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells. [Abstract]

2019 Jul;33(7):1675-1686. PMID: 30664664
J Med Chem

Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy. [Abstract]

2025 Feb 20. PMID: 39979078
Fluids Barriers CNS

Inhibition of histone deacetylase 6 activity mitigates neurological impairment and post-hemorrhagic hydrocephalus after intraventricular hemorrhage by modulating pyroptosis and autophagy pathways. [Abstract]

2025 May 7;22(1):45. PMID: 40336077
Life Sci

Targeting the HDAC6/Hint2/MICU1 axis to ameliorate acute liver failure via inhibiting NETosis. [Abstract]

2025 Apr 1:366-367:123498. PMID: 39983829
Cells

HDAC Inhibition Induces Transient Phenotypic Inertia in Dormant OCCC Spheroids by Derepression of Cell Cycle Genes. [Abstract]

2026 Apr 10;15(8):673. PMID: 42041541
Commun Biol

Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. [Abstract]

2024 Oct 4;7(1):1257. PMID: 39362994
Pharmaceuticals (Basel)

Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma. [Abstract]

2025 Aug 29;18(9):1303. PMID: 41011174
Int Immunopharmacol

Acetylation of Hint2 mitigates acute liver failure by suppressing neutrophil chemotaxis and NETosis through maintaining mitochondrial calcium and protein homeostasis. [Abstract]

2026 Mar 1:172:116254. PMID: 41570743
Int Immunopharmacol

IDH1/MDH1 deacetylation activates the cGAS-STING pathway by promoting NETosis in acute liver failure. [Abstract]

2025 Jun 17:158:114884. PMID: 40388861
Int Immunopharmacol

IDH1/MDH1 deacetylation promotes NETosis by regulating OPA1 and autophagy. [Abstract]

2024 Sep 30;143(Pt 1):113270. PMID: 39353390
Biochim Biophys Acta Mol Basis Dis

Hippocampal HDAC6 promotes POCD by regulating NLRP3-induced microglia pyroptosis via HSP90/HSP70 in aged mice. [Abstract]

2024 Jun;1870(5):167137. PMID: 38527593
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Cancers (Basel)

Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. [Abstract]

2022 Feb 3;14(3):782. PMID: 35159049
Cancers (Basel)

Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. [Abstract]

2019 Sep 7;11(9):1327. PMID: 31500290
Oncol Rep

ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. [Abstract]

2017 Feb;37(2):1270-1276. PMID: 28035401

Ricolinostat purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2017 Feb;37(2):1270-1276. [Abstract]

A375 cells are treated with indicated concentrations of ACY-1215. After 72 h, Western blotting assay are utilized to detect apoptosis.
Med Oncol

HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. [Abstract]

2016 May;33(5):50. PMID: 27090797

Ricolinostat purchased from MedChemExpress. Usage Cited in: Med Oncol. 2016 May;33(5):50. [Abstract]

H460 cells are treated with 0.5 μM Aorafenib and indicated concentration of HDAC6 inhibitors, CAY10603 (CAY, 0.05 μM) or ACY1215 (ACY,1 μM). The cleavage of PARP and caspase 3 also increased after cotreatment.
iScience

The acetylation of MDH1 and IDH1 is associated with energy metabolism in acute liver failure. [Abstract]

2024 Apr 6;27(5):109678. PMID: 38660411
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.
Theriogenology

Effect of ACY-1215 on cytoskeletal remodeling and histone acetylation in bovine somatic cell nuclear transfer embryos. [Abstract]

2022 Apr 15:183:98-107. PMID: 35231828
Anticancer Res

Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells. [Abstract]

2022 Jan;42(1):471-482. PMID: 34969757
SSRN

2026 May 21.
bioRxiv

2025 Oct 30.
bioRxiv

Metabolic STAMP for deciphering GPCR-regulated insulin secretion by pancreatic β cells. [Abstract]

2025 Oct 4:2025.10.03.680349. PMID: 41256453
University of Pittsburgh

2025.
Patent

US20250161243A1.
bioRxiv

2025 April 26.
McGill University

2023 Dec.
Research Square Print

2023 Mar 9.
Res Sq

RNA-targeted therapy corrects neuronal deficits in PACS1 syndrome mice. [Abstract]

2023 Jan 27:rs.3.rs-2440581. PMID: 36747781
bioRxiv

2021 Dec.
Patent

US20210290612A1.
bioRxiv

2021 Jan 5.
Albert-ludwigs-university Of Freiburg

2019 Dec.
Biomed Pharmacother

ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-κB signaling pathways. [Abstract]

2019 Jan:109:2464-2471. PMID: 30551507

Ricolinostat purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Jan:109:2464-2471. [Abstract]

The expression of IL-1β and IL-6 in human primary chondrocytes and C28/I2 cells is tested by western blot analysis with the treatment of IL-1β, DMSO and ACY-1215.

Ricolinostat purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Jan:109:2464-2471. [Abstract]

The expression of MMP-1, MMP-13 and COL2 A1 in C28/I2 cells is tested by western blot analysis with the treatment of IL-1β, DMSO and ACY-1215.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (115.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3068 mL

11.5340 mL

23.0681 mL

5 mM

0.4614 mL

2.3068 mL

4.6136 mL

10 mM

0.2307 mL

1.1534 mL

2.3068 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

The effect of Ricolinostat with or without PS-341 on the viability of MM cell lines, patient MM cells, and PBMCs is assessed by measuring MTT dye absorbance. PBMCs from healthy donors are isolated and stimulated with 2.5 μg/mL of phytohemagglutinin (PHA) for 48 hours in the presence of increasing concentrations of Ricolinostat (ACY-1215). DNA synthesis is measured by tritiated thymidine uptake. CD4⁺ T cells are purified from human blood with the Rosette Sep negative-selection kit. Cells are stimulated by CD3/CD28 Dynabeads for 7 days in the presence of compounds. Cell viability is assessed using alamarBlue. MM cells (2-3×10⁴ cells/well) are incubated in 96-well culture plates with medium and different concentrations of Ricolinostat (ACY-1215), PS-341, and/or recombinant IL-6 (10 ng/mL) or IGF-1 (50 ng/mL) for 24 hours at 37°C, and tritiated thymidine incorporation is measured^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
To evaluate the in vivo anti-MM activity of Ricolinostat, male SCID mice are inoculated subcutaneously with 5×10⁶ MM.1S cells in 100 μL of serum-free RPMI 1640 medium. When tumors are measurable, mice are treated IP with Ricolinostat 50 mg/kg dissolved in 10% DMSO in 5% dextrose in water consecutively for 5 days a week for 3 weeks; PS-341 0.5 mg/kg dissolved in 0.9% saline solution biweekly (IV) for 3 consecutive weeks; or combination with the same dosing regimen used for the individual agents. The control group receive the carrier alone at the same schedule as the combination group. Tumor size is measured every other day in 2 dimensions using calipers, and tumor volume is calculated with the formula: V=0.5(a×b²) where a is the long diameter of the tumor and b is the short diameter of the tumor. Mice are killed when the tumor reaches 2 cm³ or is ulcerated. Survival and tumor growth are evaluated from the first day of treatment until death.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Santo L, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with PS-341 in multiple myeloma. Blood. 2012 Mar 15;119(11):2579-89. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3068 mL	11.5340 mL	23.0681 mL	57.6701 mL
	5 mM	0.4614 mL	2.3068 mL	4.6136 mL	11.5340 mL
	10 mM	0.2307 mL	1.1534 mL	2.3068 mL	5.7670 mL
	15 mM	0.1538 mL	0.7689 mL	1.5379 mL	3.8447 mL
	20 mM	0.1153 mL	0.5767 mL	1.1534 mL	2.8835 mL
	25 mM	0.0923 mL	0.4614 mL	0.9227 mL	2.3068 mL
	30 mM	0.0769 mL	0.3845 mL	0.7689 mL	1.9223 mL
	40 mM	0.0577 mL	0.2884 mL	0.5767 mL	1.4418 mL
	50 mM	0.0461 mL	0.2307 mL	0.4614 mL	1.1534 mL
	60 mM	0.0384 mL	0.1922 mL	0.3845 mL	0.9612 mL
	80 mM	0.0288 mL	0.1442 mL	0.2884 mL	0.7209 mL
	100 mM	0.0231 mL	0.1153 mL	0.2307 mL	0.5767 mL

Bioz

Keywords

Ricolinostat

47 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ricolinostat

Vorinostat

Entinostat

Romidepsin

Tubastatin A

Panobinostat

Citarinostat

Pracinostat

Nexturastat A

Tubacin

Mocetinostat

Tacedinaline

Abexinostat

Publications Citing Use of MedChemExpress (MCE) Ricolinostat

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (47)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Ricolinostat

Vorinostat

Entinostat

Romidepsin

Tubastatin A

Panobinostat

Citarinostat

Pracinostat

Nexturastat A

Tubacin

Mocetinostat

Tacedinaline

Abexinostat

Publications Citing Use of MedChemExpress (MCE) Ricolinostat

Alle HDAC Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (47)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ricolinostat Related Classifications

HY-16026 Related Classifications

Bioz